Amgen (AMGN): FY26 Q1 earnings call, Apr 30, 2026

Thu, Apr 30Earnings callSpeaker-labelled transcriptAmgen

No Kalshi or Polymarket word markets were listed for Amgen’s Apr 30, 2026 earnings call (FY26 Q1). The transcript is searchable below (quotes of at most 25 words).

Updated

Transcript

quotes of at most 25 words

Speaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.

3 matches for “Dazodalibep”; 3 quoted, at least 25 words apart.

James Bradnercompanyprepared

…improving convenience and expanding treatment options for patients with thyroid eye disease. Dazodalibep, our first-in-class CD40 ligand targeting fusion protein continues to progress with 2…

James Bradnercompanyqa

…hard for me. We observed in Phase II very strong activity of dazodalibep which, as you comment, is a CD40 ligand Fc-targeting fusion protein. And…

James Bradnercompanyqa

…of both studies is expected in the second half of this year. Dazodalibep is a product of a long sought after drug discovery campaign, honestly,…

Agents: this page as TSV at /api/v1/appearances/amgen:2026-04-30:earnings_call · words: /api/v1/brief?appearance=amgen:2026-04-30:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP